Navigation Links
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
Date:10/29/2010

lan," "goal," "expect," "project," or similar statements, may be forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. These statements include, but are not limited to, AVANIR's ability to successfully market and sell NUEDEXTA in the United States, the safety and efficacy of NUEDEXTA, and the anticipated timing and success of the commercial launch of NUEDEXTA. Risks that could cause actual results to differ include the occurrence of adverse safety events with NUEDEXTA, our limited capital resources, our dependence on third parties for manufacturing and distribution of NUEDEXTA, that we may not adequately build or maintain the necessary sales, marketing, supply chain management and reimbursement capabilities on our own or enter into arrangements with third parties to perform these functions in a timely manner or on acceptable terms, and other risks that are described in further detail in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to time in other publicly available information regarding the Company. Copies of this information are available from us upon request. We disclaim any intent to update these forward-looking statements.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014  Rigrodsky & Long, P.A.: , ... Inc. (NYSE: LCI )? , Did you purchase ... and July 16, 2014, inclusive? , Did you lose ... Do you want to discuss your rights? ... States Attorney, Timothy J. MacFall , announces that a complaint ...
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 ... market research report is available in its ... Market Forecast 2014-2024 ... Needle-free delivery – discover technological and commercial ... the needle-free delivery market? Visiongain,s brand new ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: North ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North America ... GlobalData,s new report, "North America Laparoscopes Market Outlook ... North America Laparoscopes market. The report provides value, ...
Breaking Medicine Technology:Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11
... 18, 2010 Cell Therapeutics, Inc. ("CTI") (Nasdaq ... Authorization Application ("MAA") seeking approval for Pixuvri™ (pixantrone ... multiply relapsed or refractory aggressive non-Hodgkin,s lymphoma ("NHL") ... European Medicines Agency ("EMA"). Validation indicates that the ...
... 17, 2010 RetireSafe, a 400,000-supporter strong national ... Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) ... to the important new Provenge treatment procedure for ... the Committee to "consider not only the many ...
Cached Medicine Technology:The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3RetireSafe Urges Support for Provenge Prostate Cancer Treatment 2
(Date:8/29/2014)... Pursuing its deepest desires to help build ... stunning new design that promises to redefine the global ... surrogacy platform has witnessed a 42 percent increase in ... month, the FindSurrogateMother.com community is formed by hopeful parents ... — the precious gift of life. , Whether intended ...
(Date:8/29/2014)... News) -- If you have bunions, taking care of them ... expert says. A bunion is a bump that forms ... tissue moves out of place and extends beyond the normal ... pain and may require surgery to correct, said Brent Rosenthal, ... Freehold, N.J. To prevent bunions, avoid wearing shoes with ...
(Date:8/29/2014)... NEW YORK August 29, 2014 - Despite US ... obesity, there are many barriers, several of which may ... study by researchers at NYU Langone Medical Center published ... General Internal Medicine ( JGIM ). , David ... Department of Internal Medicine at NYU Langone, and colleagues ...
(Date:8/29/2014)... AURORA, Colo. (Sept. 2, 2014) A team of ... has reported the breakthrough discovery of a process to ... patients. These findings could have implications that extend beyond ... and autoimmune diseases., In an article published ... the Charles C. Gates Center for Regenerative Medicine and ...
(Date:8/29/2014)... 29, 2014 Today, NBC’s “The ... who profiled a handful of safe, back to ... Research. This year, many schools will include earphones ... innovator of hearing wellness solutions, offers the best ... Earphones, offered in yellow, pink and black, sound ...
Breaking Medicine News(10 mins):Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Take Steps to Control Bunions 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2
... addictions to stimulants tend to choose instant gratification or a ... the future reward is greater. Reduced value of a ... challenge for treatment of addiction. A new study in the ... appears to present a strategy for increasing the value of ...
... Jan. 27 (HealthDay News) -- About one-fourth of all black ... their risk for coronary artery disease, new research reveals. ... linked to a higher risk for heart disease ... that in black men and women who carry this single ...
... Patients with obstructive sleep apnea who undergo surgery to improve ... less drowsy during the day, according to a new study ... study finds surgery greatly reduces daytime sleepiness a common ... is partially or completely blocked during sleep when compared ...
... 27, 2011 Screening patients in the intensive care ... savings for the whole hospital, according to a study ... February issue of the American Journal of Infection ... Association for Professionals in Infection Control and Epidemiology. ...
... Injury Research and Policy of The Research Institute at ... adolescents 6 to 18 years old and found that ... departments from 1994 through 2007, for an average of ... study period, the annual number of running-related injuries increased ...
... HealthDay Reporter , THURSDAY, Jan. 27 (HealthDay News) ... hot flashes and other menopausal symptoms: Your risk for breast ... from the Fred Hutchinson Cancer Research Center in Seattle report. ... risk, and we also know that menopausal symptoms occur primarily ...
Cached Medicine News:Health News:Memory training explored as strategy for addiction treatment 2Health News:Memory training explored as strategy for addiction treatment 3Health News:Gene Mutation May Protect Blacks From Heart Disease 2Health News:Surgery for obstructive sleep apnea reduces daytime drowsiness 2Health News:Study finds MRSA screening saves hospitals money 2Health News:Study Ties Hot Flashes to Lower Breast Cancer Risk 2Health News:Study Ties Hot Flashes to Lower Breast Cancer Risk 3
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... anesthesia solution for the MRI environment , ... ,The Narkomed MRI-2 is the only ... monitor, designed and engineered to perform, without distance ... environments of up to 3.0 Tesla. This feature ...
... Narkomed GS provides high quality ventilation ... The proven technologies of the AV2+ ... the Narkomed GS user-friendly and intuitive. ... quality Narkomed GS is the perfect ...
... facilities where space is a premium Fabius ... delivery technologies with an ergonomic and compact ... of the Draeger Infinity patient monitoring range ... environment that is a sound investment into ...
Medicine Products: